Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris is a promising biopharmaceutical company that has a potential blockbuster drug in deucrictibant, with a differentiated oral prophylactic treatment for hereditary angioedema (HAE). The company has a strong track record of meeting development timelines, with a Phase 2 study demonstrating an 84.5% reduction in attack rates and open-label extension data maintaining improvements. A successful Phase 3 readout in the third quarter of 2026 could position deucrictibant as a competitive option against injectable therapies. The company remains well-funded with €292M in cash and is expected to submit an NDA for on-demand deucrictibant in the first half of 2026. However, potential future financing may be necessary. Overall, the positive potential for deucrictibant and the company's strong management team make it a favorable investment opportunity.

Pharvaris is a late-stage biopharmaceutical company with a concentrated pipeline focused on developing oral bradykinin B2 receptor antagonists for HAE. While positive data in Phase 2 studies is promising, there is a high level of risk associated with concentrating on one mechanism of action for one indication. Additional concerns include the potential for efficacy and safety issues with chronic dosing, competition in the HAE market, and the company's lack of commercial infrastructure. Regulatory uncertainties and the need for additional capital also add to the negative outlook.